Phase II Trial Assessing Granulocyte-macrophage—Colony Stimulating Factor, Ketoconazole Plus Mitoxantrone in Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Treatments

REFERENCES

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10–29.
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med 1999;341(24):1837–1838.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• Petrylak DP. Docetaxel for the treatment of hormone-refractory prostate cancer. Rev Urol 2003;5(Suppl 2):S14–S21.
   Google Scholar
• Simons JW, Small E, Nelson W, Nemunaitis J, Centeno A, Dula E, Urba W, Smith D, Marshall F, Borellini F, Sy J, Marshall M. Phase II Trials of a GM-CSF Gene-Transduced Prostate Cancer Cell Line Vaccine (GVAX) Demonstrate Anti-Tumor Activity. Proc Am Soc Clin Oncol 2001;20:(abstr 1073).
   Google Scholar
• Rini BI, Weinberg V, Bok R, Small EJ. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 2003;21(1): 99–105.
   PubMed Web of Science ®Google Scholar
• Small EJ, Halabi S, Picus J, Chen Y, Vogelzang NJ. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc Am Soc Clin Oncol 2001;20:(abstr 695);
   Google Scholar
• Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997;157(4):1204–1207.
   PubMed Web of Science ®Google Scholar
• Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997;80(9): 1755–1759.
   PubMed Web of Science ®Google Scholar
• Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002;168(2):542–545.
   PubMed Web of Science ®Google Scholar
• Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 1994;12(4): 683–688.
   PubMed Web of Science ®Google Scholar
• Fisher GR, Patterson LH. Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin. Cancer Chemother Pharmacol 1992;30(6):451–458.
   PubMed Web of Science ®Google Scholar
• Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992;19(5):529–542.
   PubMed Web of Science ®Google Scholar
• Eklund J, Kozloff M, Vlamakis J, Starr A, Mariott M, Gallot L, Jovanovic B, Schilder L, Robin E, Pins M, Bergan RC. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. Cancer 2006;106(11):2459–2465.
   PubMed Web of Science ®Google Scholar
• Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O; Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008;179(6):2181–2185; discussion 5–6.
   PubMed Web of Science ®Google Scholar
• Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol: Official Journal of the American Society of Clinical Oncology 1997;15(1):382–388.
   PubMed Web of Science ®Google Scholar
• Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol: Official Journal of the American Society of Clinical Oncology 1993;11(4):607–615.
   PubMed Web of Science ®Google Scholar
• Scher HI, Curley T, Geller N, Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol: Official Journal of the American Society of Clinical Oncology 1990;8(11): 1830–1838.
   PubMed Web of Science ®Google Scholar
• Scher HI, de Bono JS. A phase 3, randomized, double-blind, placebo-controlled study of abiraterone acetate (CB7630) plus prednisone in patients with metastatic castration-resistant prostate cancer who have failed Docetaxel-based chemotherapy. In ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2012-08-22]; Available at: http://clinicaltrials. gov/show/NCT00638690 NLM Identifier: NCT00638690.
   Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators.Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 2012;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Parker C, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Demkow T, Logue JP, Seke M, Widmark A, Johannessen DC, Nilsson S, Hoskin P, Solberg A, James ND, Syndikus I, Cross A, O'Bryan-Tear CG, Garcia-Vargas JE, Sartor AO. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. 2012 Genitourinary Cancers Symposium; J Clin Oncol J Clin Oncol 2012;30: (suppl 5; abstr 8).
   Google Scholar